RATIONALE: Macrophages change their phenotype and biological functions depending on the microenvironment. In atherosclerosis, oxidative tissue damage accompanies chronic inflammation; however, macrophage phenotypic changes in response to oxidatively modified molecules are not known. OBJECTIVE: To examine macrophage phenotypic changes in response to oxidized phospholipids that are present in atherosclerotic lesions. METHODS AND RESULTS: We show that oxidized phospholipid-treated murine macrophages develop into a novel phenotype (Mox) that is strikingly different from the conventional M1 and M2 macrophage phenotypes. Compared to M1 and M2, Mox macrophages show a different gene expression pattern, as well as decreased phagocytotic and chemotactic capacity. Treatment with oxidized phospholipids induces both M1 and M2 macrophages to switch to the Mox phenotype. Whole-genome expression array analysis and subsequent gene ontology clustering revealed that the Mox phenotype was characterized by abundant overrepresentation of Nrf2-mediated expression of redox-regulatory genes. In macrophages isolated from Nrf2(-/-) mice, oxidized phospholipid-induced gene expression and regulation of redox status were compromised. Moreover, we found that Mox macrophages comprise 30% of all macrophages in advanced atherosclerotic lesions of low-density lipoprotein receptor knockout (LDLR(-/-)) mice. CONCLUSIONS: Together, we identify Nrf2 as a key regulator in the formation of a novel macrophage phenotype (Mox) that develops in response to oxidative tissue damage. The unique biological properties of Mox macrophages suggest this phenotype may play an important role in atherosclerotic lesion development as well as in other settings of chronic inflammation.
RATIONALE: Macrophages change their phenotype and biological functions depending on the microenvironment. In atherosclerosis, oxidative tissue damage accompanies chronic inflammation; however, macrophage phenotypic changes in response to oxidatively modified molecules are not known. OBJECTIVE: To examine macrophage phenotypic changes in response to oxidized phospholipids that are present in atherosclerotic lesions. METHODS AND RESULTS: We show that oxidized phospholipid-treated murine macrophages develop into a novel phenotype (Mox) that is strikingly different from the conventional M1 and M2 macrophage phenotypes. Compared to M1 and M2, Mox macrophages show a different gene expression pattern, as well as decreased phagocytotic and chemotactic capacity. Treatment with oxidized phospholipids induces both M1 and M2 macrophages to switch to the Mox phenotype. Whole-genome expression array analysis and subsequent gene ontology clustering revealed that the Mox phenotype was characterized by abundant overrepresentation of Nrf2-mediated expression of redox-regulatory genes. In macrophages isolated from Nrf2(-/-) mice, oxidized phospholipid-induced gene expression and regulation of redox status were compromised. Moreover, we found that Mox macrophages comprise 30% of all macrophages in advanced atherosclerotic lesions of low-density lipoprotein receptor knockout (LDLR(-/-)) mice. CONCLUSIONS: Together, we identify Nrf2 as a key regulator in the formation of a novel macrophage phenotype (Mox) that develops in response to oxidative tissue damage. The unique biological properties of Mox macrophages suggest this phenotype may play an important role in atherosclerotic lesion development as well as in other settings of chronic inflammation.
Authors: A D Watson; G Subbanagounder; D S Welsbie; K F Faull; M Navab; M E Jung; A M Fogelman; J A Berliner Journal: J Biol Chem Date: 1999-08-27 Impact factor: 5.157
Authors: K Dobashi; M Aihara; T Araki; Y Shimizu; M Utsugi; K Iizuka; Y Murata; J Hamuro; T Nakazawa; M Mori Journal: Clin Exp Immunol Date: 2001-05 Impact factor: 4.330
Authors: Jacqui M Marzec; Jason D Christie; Sekhar P Reddy; Anne E Jedlicka; Hue Vuong; Paul N Lanken; Richard Aplenc; Tae Yamamoto; Masayuki Yamamoto; Hye-Youn Cho; Steven R Kleeberger Journal: FASEB J Date: 2007-03-23 Impact factor: 5.191
Authors: Petra Ijäs; Krista Nuotio; Jani Saksi; Lauri Soinne; Eija Saimanen; Marja-Liisa Karjalainen-Lindsberg; Oili Salonen; Seppo Sarna; Jarno Tuimala; Petri T Kovanen; Markku Kaste; Perttu J Lindsberg Journal: Arterioscler Thromb Vasc Biol Date: 2006-11-09 Impact factor: 8.311
Authors: Elena Galkina; Alexandra Kadl; John Sanders; Danielle Varughese; Ian J Sarembock; Klaus Ley Journal: J Exp Med Date: 2006-05-08 Impact factor: 14.307
Authors: Akshaya K Meher; Poonam R Sharma; Vitor A Lira; Masayuki Yamamoto; Thomas W Kensler; Zhen Yan; Norbert Leitinger Journal: Free Radic Biol Med Date: 2012-02-24 Impact factor: 7.376
Authors: Alexander W Lohman; Marie Billaud; Adam C Straub; Scott R Johnstone; Angela K Best; Monica Lee; Kevin Barr; Silvia Penuela; Dale W Laird; Brant E Isakson Journal: J Vasc Res Date: 2012-06-26 Impact factor: 1.934
Authors: Huaiping Yuan; Sami Zelkha; Sami Zelka; Marina Burkatovskaya; Rohit Gupte; Susan E Leeman; Salomon Amar Journal: Proc Natl Acad Sci U S A Date: 2013-12-09 Impact factor: 11.205